1208-75-9

Usage

Uses

Used in Pharmaceutical Industry:
1-BENZYL-HEXAHYDRO-4H-AZEPIN-4-ONE is used as a key intermediate in the synthesis of various pharmaceuticals and research chemicals. Its unique molecular structure allows it to be a versatile building block for the development of new drugs with potential therapeutic applications.
Used in Medicinal Chemistry Research:
1-BENZYL-HEXAHYDRO-4H-AZEPIN-4-ONE is utilized as a subject of research for its potential psychoactive properties and therapeutic effects. Its benzyl group and nitrogen-containing ring structure make it an interesting candidate for exploring new pharmacological effects and applications in the field of medicinal chemistry.
Further research is being conducted to fully understand and harness the potential of 1-BENZYL-HEXAHYDRO-4H-AZEPIN-4-ONE in the pharmaceutical industry, with the aim of discovering new treatments and advancing our understanding of its pharmacological properties.

InChI:InChI=1/C13H17NO/c15-13-7-4-9-14(10-8-13)11-12-5-2-1-3-6-12/h1-3,5-6H,4,7-11H2

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 615-53-2 ethyl N-methyl-N-nitrosocarbamate 
• 1216-04-2 N-(2-Cyanoethyl)-N-(3-cyanopropyl)-benzylamine 
• 1164-14-3 ethyl 4-(N-benzyl-N-(2-ethoxycarbonylethyl))aminobutyrate 
• 706-03-6 3-(benzylamino)propionitrile 
• 1454-53-1 ethyl 1-benzyl-4-oxopiperidine-3-carboxylate hydrochloride 
• 105416-56-6 1-aza-5-oxocycloheptane 
• 100-52-7 benzaldehyde 
• 50492-22-3 azepan-4-one hydrochloride 
• 100-39-0 benzyl bromide 
• 100-46-9 benzylamine 
• 23583-21-3 ethyl-3-benzylamino propionate 

Downstream Products

• 109162-29-0 1-benzyl-4-hydroxyhexahydro-1H-azepine 
• 1047675-63-7 ethyl 2-(1-benzyl-4-hydroxyazepan-4-yl)acetate 
• 71546-49-1 1-benzyl-4-(2-hydroxymethyl-phenyl)-azepan-4-ol 
• 109105-51-3 1-benzyl-hexahydro-azepin-4-ylamine 
• 1246509-80-7 9-benzyl-2,4-dioxo-3,9-diazaspiro[5.6]dodecane-1,5-dicarbonitrile 
• 344304-24-1 1-benzyl-5-chloro-2,3, 6,7-tetrahydro-1H-azepine-4-carbaldehyde 
• 49569-46-2 1-benzyl-5-bromohexahydroazepin-4-one hydrobromide 
• 514842-96-7 1-benzyl-5-bromo-azepan-4-one 
• 1582767-31-4 C₁₇H₂₁N₃O₂ 
• 1582767-32-5 C₁₇H₂₁N₃O₂ 
• 1582767-33-6 C₁₇H₂₁N₃O₂ 
• 478832-21-2 4-hydroxy-hexahydro-1H-azepine-1-carboxylic acid 1,1-dimethylethyl ester 
• 1308384-26-0 1-oxa-3,8-diazaspiro[4.6]undecan-2-one 

Relevant academic research and scientific papers

MUSCARINIC RECEPTOR AGONISTS

This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where m, p, q, W, Z, Y, X1, X2, R1, R2 R3 and R4 are as defined herein.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

1,2,4 -TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA

This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

New methylene homologation method for cyclic ketones

Teaching new tricks to an old dog: By intercepting adducts between ketones and lithium trimethylsilyldiazomethane, a new Tiffeneau-Demjanov type methylene homologation could be realized in a single-step operation. Among proton sources and Lewis acids, silica gel was found to be the most effective reagent for the protonation of intermediates and their subsequent ring expansion (see scheme). Copyright

NOVEL COMPOUNDS

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2, R3 and R4 are defined as in the description, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.

NOVEL COMPOUNDS

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2, R3 and R4 are defined as mentioned in the description, the tautomers thereof, the isomers thereof, the diastereomers thereof, the enantiomers thereof, the hydrates thereof, the mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.

Substituted Spiro-amide Compounds

Substituted spiro-amide compounds corresponding to formula I in which R5 through R8, D, X, Y and Z have defined meanings, processes for preparing such spiro-amide compounds, pharmaceutical compositions containing such compounds, and methods of using such spiro-amide compounds for treating and/or inhibiting disorders or disease states mediated at least in part by the bradykinin 1 receptor.

Gold-catalyzed efficient synthesis of azepan-4-ones via a two-step [5+2] annulation

A surprisingly efficient synthesis of azepan-4-ones via a two-step [5+2] annulation is developed. This reaction involves a key gold catalysis and shows generally high regioselectivities and good to excellent diastereoselectivities.

HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF

Provided herein are spiro-cyclic compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including, e.g., neurological disorders and metab